Global Zanamivir Market Outlook 2016-2021

Pharmaceutical

Zanamivir 2016 report studies in Global Market, especially in Europe, North America, South America, Asia (Excluding China), China and ROW, with definitions, classifications, applications and industry chain structure, development trends, competitive landscape analysis, and key regions development and import/export status to 2021.



Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.

This report provides detailed analysis of worldwide markets for Zanamivir from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Zanamivir market and further lays out an analysis of the factors influencing the supply/demand for Zanamivir, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

GCC’s report, Global Zanamivir Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Zanamivir market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Zanamivir market are GlaxoSmithKline (UK), Simcere (China), Lunan Pharmaceutical (China), among others.

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Zanamivir industry has been provided.

Table of Contents


Part 1. Scope of Report
1.1 Methodology
1.2 Geographic Scope
1.3 Years Considered

Part 2. Introduction
2.1 Definition
2.2 Current Scenario
2.2 Future Scenario

Part.3 Value Chain Analysis
3.1 Upstream
3.2 Downstream

Part 4. Manufacture
4.1 Manufacturing Process
4.2 Issues and Trends
4.3 Manufacturing Costs

Part 5. Worldwide Key Vendors
5.1 Company A
5.1.1 Business Overview
5.1.2 Products Offered
5.1.3 Business Performance
5.2 Company B
5.3 Company C
5.4 Company D
5.5 Company E
5.6 Company F
5.7 Company G
5.8 Company H
5.9 Company I
5.10 Company J

Part 6. Market Overview
6.1 Global Production Volume 2011-2016
6.2 Production Volume by Region 2011-2016
6.2.1 North America
6.2.2 EMEA
6.2.3 Asia-Pacific
6.2.4 ROW
6.3 Global Production Value 2011-2016
6.4 Production Value by Region
6.4.1 North America
6.4.2 EMEA
6.4.3 Asia-Pacific
6.4.4 ROW

Part 7. Consumption Pattern
7.1 Regional Consumption
7.1.1 North America
7.1.2 EMEA
7.1.3 Asia-Pacific
7.1.4 ROW
7.2 Global Consumption by Application

Part 8. Market Forecast
8.1 Market Size by Volume
8.1.1 North America
8.1.2 EMEA
8.1.3 Asia-Pacific
8.1.4 ROW
8.2 Market Size by Value
8.2.1 North America
8.2.2 EMEA
8.2.3 Asia-Pacific
8.2.4 ROW
8.3 Regional Consumption Forecast
8.3.1 North America
8.3.2 EMEA
8.3.3 Asia-Pacific
8.3.4 ROW
8.4 Consumption Forecast by Application

Part 9. Market Dynamics
9.1 Market Drivers
9.2 Market Constraints
9.3 Market Strategies

Part 10 Key Events
10.1 Mergers & Acquisitions
10.2 New Product Launches
10.3 Expansions
10.4 Other Developments


Inquiry Before Buying



Request For Sample